CELEX: 31994M0480
Language: en
Date: 1994-08-12 00:00:00
Title: COMMISSION DECISION of 12/08/1994 declaring a concentration to be compatible with the common market (Case No IV/M.480 - Sanofi / Kodak) according to Council Regulation (EEC) No 4064/89 (Only the English text is authentic)

Avis juridique important

|

31994M0480

COMMISSION DECISION of 12/08/1994 declaring a concentration to be compatible with the common market (Case No IV/M.480 - Sanofi / Kodak) according to Council Regulation (EEC) No 4064/89 (Only the English text is authentic)  

Official Journal C 252 , 09/09/1994 P. 0002

 COMMISSION DECISION of 12/08/1994 declaring a concentration to be compatible with the  common market (Case No IV/M.480 - Sanofi / Kodak) according to Council Regulation (EEC) No  4064/89  (Only the English text is authentic).  The paper version of the decision is available through the sales offices of the Office of Official  Publications of the European Communities. PUBLIC VERSION MERGER PROCEDURE ARTICLE 6(1)(b) DECISION To the notifying party Dear Sirs, Subject:<ind> Case no. IV/M.480 - SANOFI/KODAK <ind> <ind> Notification of 12.7.1994 pursuant to Article 4 of Council Regulation No 4064/89 1.<ind> The above mentioned notification concerns an agreement between Sanofi, Sterling  Winthrop and Eastman Kodak Company (Kodak), by which Sterling Winthrop agrees to transfer its  ethical pharmaceutical activities to Sanofi. 2.<ind> After examination of the notification, the Commission has concluded that the notified  operation falls within the scope of application of Council Regulation No 4064/89 and does not raise  serious doubts as to its compatibility with the common market. I.<tab> THE PARTIES 3.<ind> Sanofi is a French company, controlled by Elf Aquitaine, active in three key sectors: human  health, agro and food business and perfumes and cosmetics. 4.<ind> Sterling Winthrop is a wholly-owned subsidiary of Kodak.  It is active in the pharmaceutical  industry, household cleaning, and other products. 5.<ind> In 1991, Sanofi and Sterling Winthrop entered into a number of agreements by which they  combined their ethical prescription activities worldwide (excluding Japan) and their European over- the-counter (OTC) human pharmaceutical activities.  Since then, the ethical business has been  carried out as a joint venture under the name Sanofi Winthrop.  This operation was approved by the  Commission under Article 6(1)(b) of the Merger Regulation (Commission Decison of 10.6.1991 in  case IV/M.72 - Sanofi/Sterling Drug). II.<tab> THE OPERATION 6.<ind> Sterling Winthrop is transferring its ethical pharmaceutical activities, which had been  merged into the joint venture Sanofi Winthrop, to Sanofi. III.<tab> CONCENTRATION 7.<ind> The operation can be characterized as the acquisition by Sanofi of full control over Sanofi  Winthrop.  The acquisition by one of the parents of sole control over a concentrative joint venture is  a concentration within the meaning of Article 3(1)(b) of the Merger Regulation (see Commission  Decision of 28.11.1990 in case IV/M.23, ICI/Tioxide). IV.<tab> COMMUNITY DIMENSION 8.<ind> The aggregate worldwide turnover of the undertakings concerned exceeds 5,000 million  ECU [deleted business secrets]. With regard to aggregate Community-wide turnover each of the two  undertakings concerned exceeds the 250 million ECU threshold laid down in the Regulation.   Finally, none of the undertakings achieves two-thirds of its turnover within one and the same  Member State. 9.<ind> Therefore, the concentration has a Community dimension. V.<tab> COMPATIBILITY WITH THE COMMON MARKET 10.<ind> Relevant product market <ind> In its decision of 10.6.1991, the Commission stated (paragraph 14) : "the third level classes of  the ATC classification provide a grouping of medicines according to their therapeutic properties,  that is, their intended use, and therefore may be accepted as an operational market definition.  It may  be necessary, however, to carry out analysis at other levels of ATC classification where it is  appropriate to group particular 3rd level categories together or to descend to narrower classes at the  4th level". In accordance with this statement, which is still valid, the concentration affects a number  of separate product markets. It is not necessary, however, to define precisely these product markets  since, with two exceptions, discussed below, the operation does not give rise to serious doubts, even  on a narrow market definition.  11.<tab> Geographical reference market <ind> In its decision of 10.6.1991, the Commission had considered that ethical pharmaceutical  markets remain essentially national because the industry operates in a very tight legal framework  and prices of ethical drugs are directly or indirectly regulated by national laws.  Even if there is a  trend towards harmonization within the EU (Centralized Market Authorization Procedure to be  entered into force in 1995, setting up of a European Medicines Evaluation Agency), the grant of a  product license will still remain a national decision except for biotech/high level medicines.   Therefore, the Commission is of the opinion that the geographic market for ethical pharmaceutical  products remains essentially national. 12.<tab> Assessment <ind> The move from joint control in a concentrative joint undertaking to sole control does not lead  to any material change in market structure in the present case.  There is no horizontal overlap  between Sanofi and Sanofi Winthrop since Sanofi's ethical pharmaceutical activities were transferred  to Sanofi Winthrop in 1991.  The competitive position of Sanofi Winthrop's ethical pharmaceutical  activities is not strengthened by the fact that Sanofi will no longer share control with Kodak.    Moreover, Sanofi Winthrop's market position has not been strengthened to any appreciable extent  since the joint venture was established, with two exceptions  in which the joint venture has achieved  high market shares. In the case of platelet aggregation inhibitors in Greece, the market segment  concerned is extremely small but is fast-growing and, furthermore, there are many generic products  in the same market. With respect to injectable anticoagulants in Portugal, the market segment is  even smaller but easily contestable by a powerful competitor, Rhône Poulenc, which has entered the  market. For the above reasons the Commission considers that there is no strengthening of a  dominant position on these market segments. Likewise the structure of the market has not been  significantly modified. Finally, there is no significant conglomerate effect between Elf Aquitaine and  Sanofi Winthrop. VI.<tab> CONCLUSION <ind> The Commission has decided for the above reasons not to oppose the notified operation and to  declare it compatible with the common market and with the functioning of the EEA agreement.   This decision is adopted in application of Article 6(1)b of Council Regulation No 4064/89 and article  57 of the EEA agreement. For the Commission,